

ODNASS Early Cancer Screening System

Investor Executive Summary | Updated May 2026 | Seed SAFE US \$1.5M — US \$890K closed (59%) / US \$610K remaining

Odnass is transforming early cancer detection through **direct cfDNA quantification from plasma** — a rapid, affordable, scalable method using AI, Graph Neural Networks (GNN), and Blockchain — enabling **multi-cancer detection at the non-symptomatic stage**, with target TOT under 3 hours and target cost below US \$100/test.

Value Proposition

Blood-based multi-cancer screening that detects early neoplastic changes directly from plasma — no sequencing, no column extraction. Combines simplified cfDNA quantification with AI/GNN analytics and blockchain data security. Positioned as a **proof-first, partner-led diagnostics platform**; this raise underwrites measurable technical proof at Proof-of-Concept, not narrative scale.

Company Background

Australian-based MedTech/AI biotech. Provisional patent **AU 2025902937** filed July 2025. Laboratory and validation infrastructure established in EU; Proof-of-Concept activity underway in 2026.

Leadership Team

- Dr Velimir Pajic** — CEO & Co-Founder. Medical scientist (MBBS Belgrade; BSc Curtin; MIT xPRO; Judge Business School at the University of Cambridge). Clinical science, modelling, medtech commercialisation.
- Tadej Tofant** — CTO & Co-Founder. Data science, ML, instrument development; NATO-funded blood-based defence research; banking + medtech infrastructure.
- Dr Zeljko Perdija** — COO & Co-Founder. Internal medicine specialist (pulmonology, gastroenterology); Medical Director; lab workflow and platform deployment.
- Chris Rowe** — Strategic Advisor & Cornerstone Investor. Cambridge MA (Econ & Law); former Chairman ASX100 Northern Star Resources (2003–2016); 30+ years ASX board and capital markets.

Research & Technology

Direct cfDNA detection from plasma with AI/GNN-enhanced signal interpretation; minimal equipment; blockchain-secured data loop for auditability, provenance, integrity, and EMR (Electronic Medical Record) integration. The patent covers detection process, AI/GNN modelling, and a blockchain layer, creating defensible barriers to entry.

Market & Distribution

Global MCED market **>US \$150B** (CAGR >13%). Long-term target: up to 60M tests/year at ~US \$100/test (**~US \$6B revenue opportunity**). Model: IP licensing or strategic acquisition. Channels: Tier-1 MedTech partners (Roche, Guardant Health, Illumina, Exact Sciences) and diagnostic networks.

Competitive Landscape

Platform	Method	TAT	Price
Galleri (Grail)	ctDNA sequencing	10–14 days	~US \$950
Quadrant Shield	ctDNA + AI	7–10 days	~US \$1,200
OncoSeek	Protein biomarkers	3–5 days	~US \$145
Odnass (target)	Direct cfDNA + AI/GNN + BC	<3 hours	<US \$100

Odnass figures reflect internal modelling and early laboratory assumptions; performance to be confirmed at PoC.

External Review & Alignment

Independent US-based investment entity (Feb 2026) concluded Odnass is **financeable as a proof-first, partner-led diagnostics platform**. SAFE gated to four milestones: (1) Analytical Validation, (2) Clinical Feasibility, (3) Workflow Economics, (4) Partner Readiness.

Financial Projection (Indicative)

Scenario	Annual Tests	Revenue	Gross Margin
Global (full scale)	60 million	US \$6 Billion	>70%
Initial regional	6 million	US \$600 Million	>70%

Indicative long-term opportunity sizing; not a forecast.

OPERATIONAL READINESS

Proof-of-Concept underway. EU-based validated lab infrastructure, patent protection, and multi-disciplinary team. Positioned for partnership, licensing, and acquisition discussions at the PoC inflection point.

Why Odnass Is Unique

- Sequencing-free detection — reduces complexity and cost
- Scalable economics enabling population-level screening
- GNN-powered analytics for deeper biological signal interpretation
- Blockchain-secured data architecture for integrity and trust
- Designed for global healthcare deployment, including emerging markets
- Experienced founders across medtech, oncology, ML/GNN, and business development.

Redefining early cancer screening through rapid, accessible, AI-driven detection.

Quick Facts

Company: Odnass Pty Ltd
Contact: Dr Velimir Pajic, CEO
Address: Perth, WA, Australia
Email: velimir.p@odnass.com
Website: www.odnass.com
Industry: MedTech / Biotechnology
Patent: AU 2025902937 — cfDNA Detection + AI/GNN + Blockchain
Raise: US \$1.5M SAFE — \$890K closed (59%) / \$610K remaining
Use of Funds: PoC gates: Analytical Validation.